Financial Contrast: Cardio Diagnostics (NASDAQ:CDIOW) and Enlivex Therapeutics (NASDAQ:ENLV)

Cardio Diagnostics (NASDAQ:CDIOW) and Enlivex Therapeutics (NASDAQ:ENLV) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings and valuation.

Insider & Institutional Ownership

1.0% of Enlivex Therapeutics shares are held by institutional investors. 12.3% of Enlivex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations and price targets for Cardio Diagnostics and Enlivex Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardio Diagnostics	0	0	0	0	0.00
Enlivex Therapeutics	1	1	1	1	2.50

Enlivex Therapeutics has a consensus price target of $247.50, suggesting a potential upside of 16,182.89%. Given Enlivex Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Enlivex Therapeutics is more favorable than Cardio Diagnostics.

Profitability

This table compares Cardio Diagnostics and Enlivex Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cardio Diagnostics	N/A	N/A	N/A
Enlivex Therapeutics	N/A	248.08%	206.39%

Earnings & Valuation

This table compares Cardio Diagnostics and Enlivex Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardio Diagnostics	$14,450.00	N/A	N/A	N/A	N/A
Enlivex Therapeutics	N/A	N/A	$1.24 billion	($8.25)	-0.18

Enlivex Therapeutics has lower revenue, but higher earnings than Cardio Diagnostics.

Summary

Enlivex Therapeutics beats Cardio Diagnostics on 8 of the 9 factors compared between the two stocks.

About Cardio Diagnostics

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.